top of page

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

  • maura169
  • Mar 1, 2022
  • 1 min read

Updated: Sep 13, 2022



Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk, high-reward IL-12 target — doing it in a deal with repeat collaborator and NK cell engager player Dragonfly Therapeutics.


As part of that deal, Vessey handed over $475 million in near-term cash in exchange for a global license for Dragonfly’s extended half-life cytokine DF6002 — a monovalent, IL-12 immunoglobulin Fc fusion protein designed to spur a targeted immune response.





 
 
 

Comments


DragonflyTherapeutics_Logo_Color_Final_07.09.16.png
Activating the Immune System to Fight Disease
Contact

DRAGONFLY Therapeutics, Inc.
180 3rd Avenue, Sixth Floor

Waltham, MA 02451
United States

1-617-588-0086

Sitemap
  • Twitter
  • LinkedIn

©2024 Dragonfly Therapeutics - All Rights Reserved

bottom of page